Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics innovator developing PCR-based testing solutions through its patented Co-Primers™ technology. This page serves as the definitive source for verified company news and announcements, providing stakeholders with timely updates on developments impacting global healthcare diagnostics.
Investors and industry professionals will find curated press releases covering financial results, regulatory milestones, product launches, and strategic partnerships. Our aggregation includes updates on CODX's expanding test menu (including tuberculosis and respiratory disease diagnostics), manufacturing expansions, and progress toward decentralized testing solutions through the Co-Dx™ platform.
Key resources include earnings call transcripts, FDA clearance announcements, and analysis of emerging market initiatives like the CoSara Diagnostics joint venture in India. All content is organized chronologically demonstrate the company's trajectory while maintaining compliance with financial disclosure standards.
Bookmark this page for direct access to primary source materials that inform investment decisions and industry analysis. Check regularly for updates on CODX's contributions to accessible, high-accuracy diagnostic testing worldwide.
Co-Diagnostics (Nasdaq: CODX) is set to showcase its advancements in molecular diagnostics at the Life Sciences Day on the Hill on February 16, 2022, in the Utah State Capital. The company has sold over 30 million COVID-19 PCR tests, marking a significant milestone two years after its first sale. CEO Dwight Egan emphasized the company's pioneering role, having received the first U.S. CE-marking for a COVID-19 test. Attendees can visit the booth from 7:00 AM to 10:00 AM to learn more about new diagnostic platforms.
Co-Diagnostics (Nasdaq: CODX) announced that its joint venture, CoSara Diagnostics, received clearance from India's Central Drugs Standard Control Organization to manufacture and sell the SARAQ™ Hepatitis B (HBV) Viral Load Kit as an in vitro diagnostic. This test, utilizing patented CoPrimer™ technology, aids in monitoring antiviral treatment responses for HBV, which claims over 800,000 lives annually. CEO Dwight Egan emphasized the growing diagnostic market for endemic diseases, while CoSara Director Mohal Sarabhai noted strong demand for the test, crucial for improving patient quality of life in India.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced it will host a booth at Medlab Middle East 2022, taking place January 24-27 at the Dubai World Trade Centre. The event is a significant gathering for the global medical laboratory community, providing a platform for introducing Co-Diagnostics' products to international clients. Company representatives will showcase innovations, including a new point-of-care and at-home rapid PCR diagnostics platform. Attendees can visit Booth Z6-C26 for more information.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its joint venture, CoSara Diagnostics, received clearance from India's CDSCO to manufacture and sell the SARAGENE™ HPV-HR Real-Time PCR test as an in vitro diagnostic. This marks the 12th CoSara assay approved in India and is designed to detect high-risk HPV genotypes, which cause significant health issues globally, including cervical cancer. Co-Diagnostics CEO emphasized the importance of accessible diagnostics in regions with low vaccination rates, while the CoSara Director noted the high demand for this test.
Co-Diagnostics, Inc. (CODX) announced its participation in the H.C. Wainwright & Co. 2022 BioConnect Conference, scheduled for January 10-13, 2022. CEO Dwight Egan will provide an On-Demand presentation focusing on recent developments related to its point-of-care and at-home diagnostic platform. The presentation will be accessible from January 10, 2022, at 7:00 am Eastern Time for registered institutional investors via the Company’s website.
Co-Diagnostics specializes in molecular diagnostics technology, offering tests that detect and analyze DNA or RNA.
Co-Diagnostics, Inc. (Nasdaq: CODX) has successfully acquired Idaho Molecular Inc. and Advanced Conceptions, Inc. for approximately 4.72 million shares and 465,000 warrants. This acquisition includes all assets and intellectual property related to their upcoming at-home/point-of-care diagnostic device. The YourTest PCR device, under development, is designed to enhance detection of diseases using advanced optics and the CoPrimer technology. CEO Dwight Egan emphasized the strategic importance of this acquisition for future growth, although the YourTest device is not yet FDA-approved for sale.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its acquisition of Idaho Molecular Inc. and Advanced Conceptions, Inc., which will become wholly owned subsidiaries. This strategic move aims to enhance the commercialization of the Eikon™ platform and YourTest™ PCR device, particularly for a COVID-19 test. The deal includes the issuance of approximately 4.72 million shares and 465,000 common warrants, expected to close by year-end 2021. The acquisition is set to streamline product development and production, leveraging the expertise of key personnel from the acquired companies.
Co-Diagnostics, Inc. (Nasdaq: CODX) has partnered with TiiCKER™, a shareholder loyalty platform, to strengthen connections with retail investors. This initiative will help CODX engage its existing investors and attract new ones through direct marketing and reward programs. TiiCKER allows investors to verify their ownership and gain access to exclusive perks, including branded apparel. CEO Dwight Egan noted that this partnership will enhance investor relations and appreciation. TiiCKER aims to tap into the 130 million retail investors in the U.S., providing opportunities for CODX to grow its investor profile.
Co-Diagnostics (Nasdaq: CODX) announced that its joint venture, CoSara Diagnostics, has received approval from the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell the SARAPLEX™ Flu A/Flu B/COVID-19 RT-PCR test. This is CoSara's fourth assay approved this year and is designed to detect influenza A, influenza B, and SARS-CoV-2, including all known variants. The test aims to aid in distinguishing between respiratory illnesses, supporting public health initiatives in India.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its COVID-19 PCR diagnostic assays remain effective against the newly discovered Omicron variant, which has over 50 mutations. The company utilized sequencing data from GISAID to confirm that none of the mutations interfere with the performance of its tests. CEO Dwight Egan expressed confidence in their diagnostics' robustness. As countries react to the variant, Co-Diagnostics continues monitoring the performance of its tests. The firm specializes in molecular diagnostics technology for various applications beyond infectious diseases.
